China National Biotec Group Company Limited clinical trials

Acquired by Sinopharm, Nov 2010 · source ↗

The registry lists 37 studies whose lead sponsor is China National Biotec Group Company Limited. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 29, 2026.

Studies

Recruiting first, then most recently updated. Showing 37 of 37. All Sinopharm studies →

• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.RecruitingNCT07377175Phase 1

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT07338851

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedActive, not recruitingNCT05091619Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of AgeActive, not recruitingNCT05839301Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella VaccineActive, not recruitingNCT05669625Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), InactivatedActive, not recruitingNCT04863638Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and AboveActive, not recruitingNCT05365724Phase 1/2

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and AboveCompletedNCT04917523Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and AboveActive, not recruitingNCT05382871Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AboveCompletedNCT04510207Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and AboveActive, not recruitingNCT05374954Phase 3

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza VaccineCompletedNCT04091880Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis PopulationStatus unknownNCT05480436Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4CompletedNCT04559204Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies VaccineStatus unknownNCT05453487Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaPCompletedNCT04054882Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years OldCompletedNCT04700618Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the ElderlyCompletedNCT04701788Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or DiabetesCompletedNCT05065879Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV InfectedStatus unknownNCT05105295Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or DiabetesStatus unknownNCT05104437Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or DiabetesStatus unknownNCT05104333Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPDStatus unknownNCT05104216Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or DiabetesStatus unknownNCT05065892Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPDStatus unknownNCT05075057Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV InfectedStatus unknownNCT05075044Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV InfectedStatus unknownNCT05075070Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPDStatus unknownNCT05075083Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4CompletedNCT04790851Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4Status unknownNCT05079152Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of the Safety and Immunogenicity of Hepatitis A VaccineStatus unknownNCT04612634Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMRStatus unknownNCT04638985Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepAStatus unknownNCT04636827Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Immunogenicity and Safety of Sabin-IPV Replacement VaccinationCompletedNCT04051736Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPVCompletedNCT04054492Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaPStatus unknownNCT04053010Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm

• Comparative Immunogenicity Study of Two Hepatitis A VaccinesStatus unknownNCT03231605Phase 4

  Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm